Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect
New code is expected to advance commercialization efforts in doctors’ offices and other outpatient settingsFRAMINGHAM, Mass., April 05, 2023 (GLOBE...
Day: April 5, 2023
Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. Related to BENDEKA® (bendamustine hydrochloride)
WOODCLIFF LAKE, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced...
CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
CareDx Exclusive Provider of dd-cfDNA Testing Services for Use in Miromatrix Clinical Trials Companies at Forefront of Alternative Organ Supply...
SiSaf Appoints Dr. Richard Goodfellow to Board of Directors
GUILDFORD, England, April 05, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announced that it has...
Notice convening the Annual General Meeting in BioPorto A/S
April 5, 2023Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes...
General Meeting’s report as of 4th of April 2023
P Press Release Ecully, April 5, 2023 – 8:30 am Report on Spineway’s CombinedGeneral Meeting of April 4, 2023 The Ordinary...
Mendus to participate in upcoming conferences in April 2023 and to hold investor call following Annual Report publication on April 17th
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the...
Notice of General Meeting and Publication of Circular
LONDON and NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the...
Addex Completes $5.0 Million Equity Financing
Proceeds to advance allosteric modulator therapeutic pipeline Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 5, 2023...
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology CompanyTM committed to more effectively...